Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.69 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.64 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.64 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.64 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.64 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.64 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | FURIN | P09958 | 1/20 | 0.48 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Robenidine SCHEMBL571510 | 1.00 | KMT2A (0.69) | KMT2ARAB9AMAPTMEN1TAAR1 | |
| Robenidine SCHEMBL17536045 | 1.00 | KMT2A (0.69) | KMT2ARAB9AMAPTMEN1TAAR1 | |
| Robenidine SCHEMBL23858311 | 1.00 | KMT2A (0.69) | KMT2ARAB9AMAPTMEN1TAAR1 | |
| Robenidine SCHEMBL23858319 | 0.98 | KMT2A (0.72) | KMT2ARAB9AMAPTMEN1TAAR1 | |
| Robenidine SCHEMBL25169352 | 0.98 | KMT2A (0.72) | KMT2ARAB9AMAPTMEN1TAAR1 | |
| Robenidine SCHEMBL30371560 | 0.98 | KMT2A (0.72) | KMT2ARAB9AMAPTMEN1TAAR1 | |
| Robenidine SCHEMBL23858320 | 0.98 | KMT2A (0.72) | KMT2ARAB9AMAPTMEN1TAAR1 | |
| Robenidine SCHEMBL30051666 | 0.82 | KMT2A (0.55) | KMT2ARAB9AMAPTMEN1TAAR1 | |
| Hydrochloric Acid SCHEMBL11850203 | 0.81 | GRIN2D (0.59) | KMT2ARAB9AMAPTMEN1TAAR1 | |
| Hydrochloric Acid SCHEMBL11838603 | 0.81 | GRIN2D (0.59) | KMT2ARAB9AMAPTMEN1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2683395-B2 | USE OF LOW DOSE IL-2 FOR TREATING TYPE 1 DIABETES | HOPITAUX PARIS ASSIST PUBLIQUE (FR) | 2026-05-20 | — | — | EP | disclosed |
| EP-3443979-B2 | IL-2 DOSAGE REGIMEN FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | HOPITAUX PARIS ASSIST PUBLIQUE (FR) | 2026-05-20 | — | — | EP | disclosed |
| EP-4710966-A1 | AUTOINJECTOR AND METHOD OF RECONSTITUTING AN AUTOINJECTOR | medmix Switzerland AG (CH) | 2026-03-18 | — | — | EP | disclosed |
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | disclosed |
| US-20260001874-A1 | DIHYDROQUINAZOLINONES EXHIBITING IMPROVED PROTECTIVE ACTIVITY AGAINST INTRACELLULARLY ACTING TOXINS AND INTRACELLULAR VIRUSES AND BACTERIA | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2026-01-01 | — | — | US | disclosed |
| US-12491232-B2 | Low dose IL-2 for treating autoimmune-related or inflammatory disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2025-12-09 | — | — | US | disclosed |
| EP-3835319-B1 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H LUNDBECK AS (DK) | 2025-11-19 | — | — | EP | disclosed |
| US-20250346567-A1 | SUBSTITUTED PYRIDINE AND PHENYL COMPOUNDS | PFIZER INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-12467053-B2 | Hybrid immunoglobulins with moving parts | BIOMOLECULAR HOLDINGS LLC (US) | 2025-11-11 | — | — | US | disclosed |
| US-12421269-B2 | SGLT2/DPP4 inhibitor and application thereof | CGENETECH (SUZHOU, CHINA) CO., LTD. (CN) | 2025-09-23 | — | — | US | disclosed |
| US-11325902-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2022-05-10 | — | — | US | disclosed |
| US-20220135668-A1 | Methods for Treating Psoriasis Using an Anti-IL-23 Antibody | AMGEN INC. | 2022-05-05 | — | — | US | disclosed |
| US-20220120754-A1 | METHOD FOR SELECTING SUBJECT LIKELY BENEFITING FROM PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-21 | — | — | US | disclosed |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2022-04-12 | — | — | US | disclosed |
| US-20220098600-A1 | METHODS FOR THE IMPROVEMENT OF PRODUCT YIELD AND PRODUCTION IN A MICROORGANISM THROUGH THE ADDITION OF ALTERNATE ELECTRON ACCEPTORS | DANSTAR FERMENT AG (CH) | 2022-03-31 | — | — | US | disclosed |
| US-20220090045-A1 | METHODS FOR PRODUCING ISOPROPANOL AND ACETONE IN A MICROORGANISM | DANSTAR FERMENT AG (CH) | 2022-03-24 | — | — | US | disclosed |
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| CN-114097815-A | Application of medical compound with amidine skeleton in resisting plant pathogenic bacteria | 兰州大学 | 2022-03-01 | — | — | CN | disclosed |
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| CN-114026079-A | SGLT2/DPP4 inhibitor and application thereof | 南京明德新药研发有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346567-A1 | SUBSTITUTED PYRIDINE AND PHENYL COMPOUNDS | PAH, PC, MPC2 | KMT2A 1935/4885RAB9A 2683/4885MAPT 1668/4885 |
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | TRPV1, HCN4, TRPA1 | KMT2A 1907/4885RAB9A 3448/4885MAPT 3785/4885 |
| US-12421269-B2 | SGLT2/DPP4 inhibitor and application thereof | SLC5A2, SLC5A1, DPP4 | KMT2A 1465/4885RAB9A 2742/4885MAPT 1787/4885 |
| US-12467053-B2 | Hybrid immunoglobulins with moving parts | IGLV6-57, FCGRT, FCGR3B | KMT2A 2337/4885RAB9A 2738/4885MAPT 2074/4885 |
| US-11325902-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | KMT2A 2321/4885RAB9A 2453/4885MAPT 144/4885 |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | KMT2A 2408/4885RAB9A 2532/4885MAPT 145/4885 |
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REN, RDX, MC2R | KMT2A 1492/4885RAB9A 752/4885MAPT 3206/4885 |
| US-20220120754-A1 | METHOD FOR SELECTING SUBJECT LIKELY BENEFITING FROM PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER | BCOR, TP53, BCL6 | KMT2A 2204/4885RAB9A 3419/4885MAPT 2782/4885 |
| US-20260001874-A1 | DIHYDROQUINAZOLINONES EXHIBITING IMPROVED PROTECTIVE ACTIVITY AGAINST INTRACELLULARLY ACTING TOXINS AND INTRACELLULAR VIRUSES AND BACTERIA | NSF, VAMP7, RAB7A | KMT2A 4685/4885RAB9A 55/4885MAPT 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.